Common multiple sclerosis treatment linked to bowel disease risk

People with aggregate sclerosis (MS) who are treated with rituximab person an accrued hazard of processing inflammatory bowel disease, peculiarly Crohn's disease, though the implicit hazard remains low. This is according to the archetypal ample population-based survey successful the field, led by researchers astatine Karolinska Institutet and published successful JAMA Neurology.